Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to $282.99.

  • Innate Pharma's Shares Outstanding (Diluted Average) fell 1523.07% to $282.99 in Q2 2025 from the same period last year, while for Jun 2025 it was $282.99, marking a year-over-year decrease of 1523.07%. This contributed to the annual value of $57.07 for FY2018, which is N/A changed from last year.
  • As of Q2 2025, Innate Pharma's Shares Outstanding (Diluted Average) stood at $282.99, which was down 1523.07% from $333.84 recorded in Q2 2024.
  • Innate Pharma's Shares Outstanding (Diluted Average)'s 5-year high stood at $95.1 million during Q2 2021, with a 5-year trough of $21.78 in Q2 2023.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $282.99 (2025), whereas its average is $19.0 million.
  • In the last 5 years, Innate Pharma's Shares Outstanding (Diluted Average) surged by 6643967036.77% in 2021 and then crashed by 9999.99% in 2022.
  • Quarter analysis of 5 years shows Innate Pharma's Shares Outstanding (Diluted Average) stood at $95.1 million in 2021, then tumbled by 100.0% to $85.36 in 2022, then crashed by 74.49% to $21.78 in 2023, then soared by 1432.87% to $333.84 in 2024, then fell by 15.23% to $282.99 in 2025.
  • Its last three reported values are $282.99 in Q2 2025, $333.84 for Q2 2024, and $21.78 during Q2 2023.